Block Drug Sensodyne Tartar Control launch bolsters U.S. sales in second quarter.
This article was originally published in The Tan Sheet
Executive Summary
BLOCK DRUG SENSODYNE TARTAR CONTROL TOOTHPASTE HELPS BOOST U.S. SALES in the second quarter (ended Sept. 30), the company reported Nov. 5. Consolidated sales for the quarter rose 18.2% to $203.5 mil. Sensodyne Tartar Control was introduced by Block Drug this autumn. The dentifrice, the fifth addition to the Sensodyne sensitive tooth line, is priced at about $4 for a 4 oz. tube. Block Drug is backing the introduction with network television ads.
|
BLOCK DRUG SENSODYNE TARTAR CONTROL TOOTHPASTE HELPS BOOST U.S. SALES in the second quarter (ended Sept. 30), the company reported Nov. 5. Consolidated sales for the quarter rose 18.2% to $203.5 mil. Sensodyne Tartar Control was introduced by Block Drug this autumn. The dentifrice, the fifth addition to the Sensodyne sensitive tooth line, is priced at about $4 for a 4 oz. tube. Block Drug is backing the introduction with network television ads. Consolidated sales increased 16.5% to $409 mil. through six months of the fiscal year. Jersey City, N.J.-based Block pointed to the "continuing strength" of its international business in Latin America, Japan, Europe and Canada as a positive factor in the second quarter performance despite the negative effects of foreign currency translation. Net income from continuing operations was up 18.3% to $5.3 mil. during the three-month period. Net income was $30.7 mil. through nine months, a gain of 13% from the comparable period of the previous fiscal year. |